What is Insmed's payment of milestone?

Insmed (INSM) reported payment of milestone of $15M in Q1 2026.

What does payment of milestone mean?

This metric represents cash payments made to third parties upon the achievement of specific clinical, regulatory, or commercial milestones. It is common in biopharmaceutical companies that license technology or assets from external partners.

Insmed INSM Payment Of Milestone

Payment Of Milestone at other companies

OS TherapiesOSTX

$22.38M0.0%

OS TherapiesOSTX

$22.38M0.0%

Royalty PharmaRPRX

$50M0.0%

CTO

Citius Oncology, Inc.CTOR

$70M+155%

HRO

HarrowHROW

$1.75M—

Climb Bio, Inc.CLYM

$8M—

Other financials

Income statement

See full

Revenue$306.0M+230%

Gross profit$258.5M+261%

Operating income-$153.3M+38.2%

Net income-$163.6M+36.3%

EPS (diluted)-$0.76+46.5%

Balance sheet

See full

Cash & equivalents$582.2M+44.4%

Total debt$580.3M-49.2%

Total equity$704.9M+611%

Total assets$2.1B+15.2%

Cash flow

See full

Operating cash flow-$222.7M+15.0%

CapEx$3.5M-65.4%

Free cash flow-$226.2M+16.9%

Valuation

See full

Market cap$23.11B+25.2%

Enterprise value$23.11B+29.9%

P/S28.2×-18.2×

Profitability

See full

Gross margin81.8%+5.3pp

Operating margin-140.6%-43.9pp

Net margin-144.4%-45.3pp

FCF margin-112.5%-35.3pp

Returns & leverage

See full

Return on equity-294.5%—

Debt / equity0.8×-10.7×

Current ratio4.5×-1.4×

Where this comes from

Reported directly by Insmed in its filing.

Tagged under the XBRL concept insm:PaymentOfMilestone.

The official record: Insmed’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insmed's payment of milestone.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Insmed's payment of milestone?: Insmed (INSM) reported payment of milestone of $15M in Q1 2026.
What does payment of milestone mean?: This metric represents cash payments made to third parties upon the achievement of specific clinical, regulatory, or commercial milestones. It is common in biopharmaceutical companies that license technology or assets from external partners.